Location History:
- Marburg, DE (2015)
- Darmstadt, DE (2022)
Company Filing History:
Years Active: 2015-2022
Title: Achim Doerner: Innovator in Cancer Treatment
Introduction
Achim Doerner is a prominent inventor based in Darmstadt, Germany. He has made significant contributions to the field of cancer treatment through his innovative work in bi-specific antibodies and aptamers. With a total of 2 patents, Doerner is recognized for his advancements in targeted therapies.
Latest Patents
Doerner's latest patents include groundbreaking inventions such as "Bi-specific antibodies for enhanced tumor selectivity and inhibition and uses thereof." This patent describes a heterodimeric bispecific immunoglobulin molecule that includes a first Fab or scFv fragment specifically binding to EGFR and a second fragment binding to c-MET. The design incorporates an antibody hinge region, CH2 domain, and CH3 domain, featuring a hybrid protein-protein interaction interface domain. This innovative approach allows for enhanced tumor selectivity through the interaction of amino acid segments within the immunoglobulin superfamily.
Another notable patent is "Bispecific aptamers mediating tumour cell lysis." This invention discloses bispecific aptamers that bind with high specificity to a tumor-specific antigen (TSA) and an effector cell-specific antigen (ESA) for effective cancer treatment. These advancements represent a significant step forward in the development of targeted cancer therapies.
Career Highlights
Achim Doerner is currently associated with Merck Patent GmbH, where he continues to push the boundaries of cancer research and treatment. His work has garnered attention for its potential to improve patient outcomes through innovative therapeutic strategies.
Collaborations
Doerner collaborates with esteemed colleagues, including Lars Toleikis and Ralf Guenther, who contribute to his research endeavors. Their combined expertise enhances the development of novel cancer therapies.
Conclusion
Achim Doerner's contributions to the field of cancer treatment through his patents and collaborations highlight his role as an influential inventor. His innovative approaches to bi-specific antibodies and aptamers pave the way for future advancements in targeted therapies.